

## Cell Line Data Sheet for CHLA-122

**Disease:** Neuroblastoma  
**Phase of Therapy:** Diagnosis  
**Treatment:** None  
**Disease Stage:** 4  
**Gender:** Female  
**Age at diagnosis:** 24 months  
**Race:** N/A  
**Age at sample collection:** N/A  
**Source of Culture:** Bone Marrow  
**Primary Tumor Site:** N/A  
**Date Established:** November 1992

**MYCN Patient:** Amplified  
**MYCN Cell line:** N/A  
**THmRNA:** Expressed  
**p53 status:** Functional  
**Telomere Mechanism:** N/A  
**ALK:** WT  
**RNAseq:** N/A  
**WES:** N/A

**Growth Conditions:** Please see Protocols section at <https://www.cccells.org/protocols.php>  
5% CO<sub>2</sub>, 20% O<sub>2</sub>, 37.0°C

**Media Formulation:** Please see Protocols section at <https://www.cccells.org/protocols.php>  
Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)

**Doubling Time:** 72 hours  
**Growth Properties:** Suspended, grow mostly in tight clumps

**STR Profile:** May be obtained at <https://strdb.cccells.org/>  
**Notes:** COGcell.org has a post-treatment cell line available from this same patient (CHLA-136). The repository has a matching EBV lymphoblastoid cell line – COG-V-450. The repository has a matching fibroblast line – COG-FB-451.

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.



---

## Cell Line Data Sheet for CHLA-122

---

**Cell Line Name:** CHLA-122

**References:**


1. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, Triche TJ, Reynolds C P: Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines. *Cancer Res.* 61:6185-6193, 2001. PubMed ID: [11507071](https://pubmed.ncbi.nlm.nih.gov/11507071/)  
<https://cancerres.aacrjournals.org/content/61/16/6185.long>
2. Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP. Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by Depsipeptide. *J Natl Cancer I.* 99: 1107-19, 2007.  
PubMed ID: [17623797](https://pubmed.ncbi.nlm.nih.gov/17623797/)  
<https://academic.oup.com/jnci/article/99/14/1107/938992>
3. Harned TM, Kalous O, Neuwelt A, Loera J, Ji L, Iovine P, Sposto R, Neuwelt EA, Reynolds CP: Sodium Thiosulfate (STS) administered six hours after cisplatin does not compromise anti-neuroblastoma activity. *Clin Cancer Res.* 14:533-540, 2008.  
PubMed ID: [18223229](https://pubmed.ncbi.nlm.nih.gov/18223229/)  
<https://clincancerres.aacrjournals.org/content/14/2/533.long>
4. Kang MH, Smith MA, Morton CL, Keshlava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. *Pediat Blood Cancer.* 56: 239-249, 2011. PubMed ID: [20922763](https://pubmed.ncbi.nlm.nih.gov/20922763/)  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/>  
  
([www.PPTPinvitro.org](http://www.PPTPinvitro.org))




## Cell Line Data Sheet for CHLA-122

Cell Line Name: CHLA-122


(10x magnification)



(10x magnification)



(20x magnification)



(20x magnification)

